Eli Lilly Ends Trial for Alzheimer's Drug Candidate
The company dropped the development of mevidalen after the drug failed to meet internal success criteria for the treatment.
Updated on Oct. 29, 2026 in Alzheimer’s
Live Poll
Do you trust that pharmaceutical companies prioritize patient health over rigid internal success metrics?
Eli Lilly has officially removed the drug candidate mevidalen from its Alzheimer's disease development pipeline. The decision follows a phase 2 trial involving 304 patients that failed to meet the company's internal criteria for success.
Why it matters
This discontinuation reflects the ongoing challenges in developing new therapies for Alzheimer's that go beyond standard care. Investors and patients often look to these programs for alternatives that target different biological pathways to address cognitive decline.
The phase 2 trial evaluated the effects of mevidalen, a dopamine D1 receptor positive allosteric modulator, on 304 patients across cognitive and functional endpoints. The program was discontinued after failing to reach the internal success thresholds required for further advancement.
The players
Eli Lilly
A global pharmaceutical company focused on developing therapies for diabetes, oncology, and neurodegenerative conditions like Alzheimer's.
The details
Mevidalen was designed to act as a positive allosteric modulator of the dopamine D1 receptor, a target theorized to influence executive function and motivation in individuals with neurodegenerative conditions. By stabilizing this receptor, the drug aimed to improve signal transmission in neural circuits associated with memory and daily tasks. However, the program concluded that the drug did not demonstrate the necessary efficacy to warrant continued testing in this patient population.
Timeline
2021: Mevidalen previously failed to reach primary endpoints in a Lewy body dementia trial.
August 2024: The phase 2 Alzheimer's disease trial for the drug began.
October 2026: Eli Lilly announced the formal termination of the Alzheimer's development program.
Health Landscape
The termination of this program highlights the difficulty of identifying successful candidates in the crowded Alzheimer's research field. It follows a period of aggressive portfolio expansion for the developer, marked by significant recent acquisitions in the biotechnology space.
This development serves as a reminder that many experimental treatments for neurodegenerative disease do not make it to clinical application. Patients and caregivers should continue to focus on evidence-based management and discuss potential clinical trial participation with their physicians.
The takeaway
Advancing new Alzheimer's treatments is a complex, iterative process where many promising candidates fail to meet high evidentiary standards. When considering new treatment options, always consult your physician to distinguish between established therapies and experimental, investigational approaches.
Further reading
For more on the current status of research into new treatments, visit Alzheimer’s.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Do you trust that pharmaceutical companies prioritize patient health over rigid internal success metrics?
